Gossamer Bio's experimental lung condition drug fails in late-stage trial
23/02/2026 13:08
Feb 23 (Reuters) - Gossamer Bio GOSS.O said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition. (Reporting by Sahil Pandey in Bengaluru; Editing by Sahal Muhammed) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing